Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background We analysed the effect of ivabradine on outcomes in heart failure (HF) patients on recommended background therapies with heart rates ≥75 bpm and <75 bpm in the SHIFT trial. A cut-off value of ≥75 bpm was chosen by the EMEA for approval for the use of ivabradine in chronic heart failure.Methods The SHIFT population was divided by baseline heart rate ≥75 or <75 bpm. The effect of ivabradine was analysed for primary composite endpoint (cardiovascular death or HF hospitalization) and other endpoints.Results In the ≥75 bpm group, ivabradine reduced primary endpoint (HR 0.76, 95 % CI 0.68-0.85, P < 0.0001), all-cause mortality (HR 0.83, 95 % CI, 0.72-0.96, P = 0.0109), cardiovascular mortality (HR 0.83, 95 % CI, (0.71-0.97, P = 0.0166), HF death (HR 0.61, 95 % CI, 0.46-0.81, P < 0.0006), and HF hospitalization (HR 0.70, 95 % CI, 0.61-0.80, P < 0.0001). Risk reduction depended on heart rate after 28 days, with the best protection for heart rates <60 bpm or reductions >10 bpm. None of the endpoints was significantly reduced in the <75 bpm group, though there were trends for risk reductions in HF death and hospitalization for heart rate <60 bpm and reductions >10 bpm. Ivabradine was tolerated similarly in both groups.Conclusion The effect of ivabradine on outcomes is greater in patients with heart rate ≥75 bpm with heart rates achieved <60 bpm or heart rate reductions >10 bpm predicting best risk reduction. Our findings emphasize the importance of identification of high-risk HF patients by high heart rates and their treatment with heart rate-lowering drugs such as ivabradine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have shown that most titration of β-blockade occurs early in the course of treatment, with most of the heart rate reduction occurring at < 50% of target dose.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [62]
Citations
Cites
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563
Self-citationCleland, J. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00823-0 · Cited by 1,549
Böhm, M., Swedberg, K., Komajda, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61259-7 · Cited by 1,099
Self-citationDiaz, A., Bourassa, M. G., Guertin, M.-C., & Tardif, J.-C. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi190 · Cited by 790
Kolloch, R., Legler, U. F., Champion, A., Cooper-DeHoff, R. M., Handberg, E., Zhou, Q., & Pepine, C. J. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehn123 · Cited by 330
Conway, M. A., Allis, J., Ouwerkerk, R., Niioka, T., Rajagopalan, B., & Radda, G. K. (1991) · The Lancet · doi:10.1016/0140-6736(91)91838-l · Cited by 322
Tardif, J.-C., O'Meara, E., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Tavazzi, L., & Swedberg, K. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr311 · Cited by 300
Self-citationMulder, P., Barbier, S., Chagraoui, A., Richard, V., Henry, J. P., Lallemand, F., Renet, S., Lerebours, G., Mahlberg-Gaudin, F., & Thuillez, C. (2004) · Circulation · doi:10.1161/01.cir.0000118464.48959.1c · Cited by 294
Current-dependent Block of Rabbit Sino-Atrial Node If Channels by Ivabradine
Bucchi, A., Baruscotti, M., & DiFrancesco, D. (2002) · The Journal of General Physiology · doi:10.1085/jgp.20028593 · Cited by 289
Custodis, F., Baumhäkel, M., Schlimmer, N., List, F., Gensch, C., Böhm, M., & Laufs, U. (2008) · Circulation · doi:10.1161/circulationaha.107.746537 · Cited by 263
Self-citation
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Self-citation2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citation2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citation2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,171
Self-citationMaddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., Masoudi, F. A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.022 · Cited by 842
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology (RSC) (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4083 · Cited by 395
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0141 · Cited by 444
Maddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Brouse, S., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.024 · Cited by 362
McDonald, M., Virani, S., Chan, M., Ducharme, A., Ezekowitz, J. A., Giannetti, N., Heckman, G. A., Howlett, J. G., Koshman, S. L., Lepage, S., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.01.017 · Cited by 287
“Studies have shown that most titration of b-blockade occurs early in the course of treatment, with most of the heart rate reduction occurring at < 50% of target dose.(62,63) With further titration, there is a diminishing effect on heart rate, leaving approximately 10%-15% of patients with residual heart rate > 70 bpm…”
BackgroundYancy, C. W., Januzzi, J. L., Allen, L. A., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Jessup, M., Lindenfeld, J., Maddox, T. M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.025 · Cited by 275
“Benefits were noted especially for those patients with: contraindications to beta blockers, beta blocker doses <50% of GDMT targets (12), and resting heart rate $77 bpm at study entry (13).”
Background2024 Clinical practice guidelines for Chronic heart failure
Galyavich, A. S., Tereshchenko, S. N., Uskach, T. M., Ageev, F. T., Aronov, D. M., Arutyunov, G. P., Begrambekova, Y. L., Belenkov, Y. N., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6162 · Cited by 204
Resting Heart Rate: Risk Indicator and Emerging Risk Factor in Cardiovascular Disease
Böhm, M., Reil, J.-C., Deedwania, P., Kim, J. B., & Borer, J. S. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.09.016 · Cited by 236
Self-citationEpidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes
Park, J. J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0282 · Cited by 171
“In patients with heart rate >75 beats/min ivabradine also showed survival benefit [80].”
BackgroundGuía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.027 · Cited by 178
Self-citationBorer, J. S., Bohm, M., Ford, I., Komajda, M., Tavazzi, L., Sendon, J. L., Alings, M., Lopez-de-Sa, E., Swedberg, K., & on behalf of the SHIFT Investigators (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs259 · Cited by 142
Self-citationIs Heart Rate Important for Patients With Heart Failure in Atrial Fibrillation?
Cullington, D., Goode, K. M., Zhang, J., Cleland, J. G. F., & Clark, A. L. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.01.005 · Cited by 144
“In patients with chronic heart failure (CHF) in SR due to left ventricular systolic dysfunction (LVSD), a lower resting heart rate is associated with better survival and fewer hospital readmissions due to heart failure (4,5).”
BackgroundPalatini, P., Rosei, E. A., Casiglia, E., Chalmers, J., Ferrari, R., Grassi, G., Inoue, T., Jelakovic, B., Jensen, M. T., Julius, S., et al. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000865 · Cited by 132
“Data obtained with the I/f-channel antagonist ivabradine in patients with congestive heart failure have been inconclusive, though there is some indication that the beneficial effect of this drug can be obtained in patients with HR higher than 70–75 bpm [72–74].”
MethodAnker, M. S., Ebner, N., Hildebrandt, B., Springer, J., Sinn, M., Riess, H. B., Anker, S. D., Landmesser, U., Haverkamp, W., & von Haehling, S. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.670 · Cited by 118
Anker, S. D., Schroeder, S., Atar, D., Bax, J. J., Ceconi, C., Cowie, M. R., Crisp, A., Dominjon, F., Ford, I., Ghofrani, H.-A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.516 · Cited by 97
“The European Medicines Agency (EMA) approved ivabradine, but only for patients with heart rates above 75 beats per minute where a possible nominal reduction in overall mortality was observed.(15) Food and Drug Administration (FDA)”
BackgroundSelf-citationThe Use of Digoxin in Patients With Worsening Chronic Heart Failure
Ambrosy, A. P., Butler, J., Ahmed, A., Vaduganathan, M., van Veldhuisen, D. J., Colucci, W. S., & Gheorghiade, M. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.051 · Cited by 99
“Ivabradine selectively inhibits the pacemaker I f current, slowing the HR by approximately 10 beats/min and thereby reducing CV morbidity and mortality (56 – 58).”
Tavazzi, L., Swedberg, K. B., Michel Komajda, N., Böhm, M., BORER, J. S., Lainščak, M., Robertson, M., & Ford, I. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.10.068 · Cited by 109
“Moreover, the magnitude of this effect was directly related to baseline heart rate and the extent of heart rate reduction [18].”
BackgroundSelf-citationHidalgo, F. J., Anguita, M., Castillo, J. C., Rodríguez, S., Pardo, L., Durán, E., Sánchez, J. J., Ferreiro, C., Pan, M., Mesa, D., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.136 · Cited by 99
Fox, K., Komajda, M., Ford, I., Robertson, M., Böhm, M., Borer, J. S., Steg, P. G., Tavazzi, L., Tendera, M., Ferrari, R., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht101 · Cited by 95
Self-citationDobre, D., BORER, J. S., Fox, K. M., Swedberg, K. B., Adams, K. F., Cleland, J. G. F., Solal, A. C., Gheorghiade, M., Gueyffier, F., O’Connor, C. M., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft129 · Cited by 90
“(n 1⁄4 4150).(23) CV, cardiovascular; HF, heart failure.”
BackgroundSelf-citationEfficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure ― J-SHIFT Study ―
Tsutsui, H., Momomura, S., Yamashina, A., Shimokawa, H., Kihara, Y., Saito, Y., Hagiwara, N., Ito, H., Yano, M., Yamamoto, K., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0227 · Cited by 77
Renal sympathetic denervation: applications in hypertension and beyond
Böhm, M., Linz, D., Urban, D., Mahfoud, F., & Ukena, C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.89 · Cited by 79
Self-citationIvabradine for the Treatment of Cardiovascular Diseases
Ide, T., Ohtani, K., Higo, T., Tanaka, M., Kawasaki, Y., & Tsutsui, H. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-1184 · Cited by 73
Michel Komajda, N., Böhm, M., BORER, J. S., Ford, I., Robertson, M., Manolis, A. J., Tavazzi, L., & Swedberg, K. B. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.114 · Cited by 72
Self-citationHaghikia, A., Podewski, E., Berliner, D., Sonnenschein, K., Fischer, D., Angermann, C. E., Böhm, M., Röntgen, P., Bauersachs, J., & Hilfiker-Kleiner, D. (2015) · Clinical Research in Cardiology · doi:10.1007/s00392-015-0869-5 · Cited by 65
“Both groups are additionally treated with standard heart failure medication as per current guidelines [14–17].”
MethodSelf-citationGriffiths, A., Paracha, N., Davies, A., Branscombe, N., Cowie, M., & Sculpher, M. (2014) · Heart · doi:10.1136/heartjnl-2013-304598 · Cited by 70
Ivabradine: Role in the Chronic Heart Failure Armamentarium
Psotka, M. A., & Teerlink, J. R. (2016) · Circulation · doi:10.1161/circulationaha.115.018094 · Cited by 73
“Because higher β-blocker dosing correlated with lower baseline HR, the increased HR cutoff potentially addressed the lack of benefit seen for ivabradine both below an HR of 75 bpm and with higher β-blocker dosing.(54,57) Both agencies contraindicated ivabradine with significant sinoatrial or atrioventricular block in…”
BackgroundBöhm, M., Robertson, M., Ford, I., BORER, J. S., Komajda, M., Kindermann, I., Maack, C., Lainščak, M., Swedberg, K. B., & Tavazzi, L. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.09.029 · Cited by 70
“Heart rate reduction with ivabradine reduces the composite end point ofCVdeath andHFhospitalization at heart rates 70 beats/min(10,11) and even CV death and all-cause death in patients with a heart rate 75 beats/min.(14) According to previous analyses from SHIFT, the treatment effect of ivabradine was maintained in pa…”
MethodSelf-citationBöhm, M., Borer, J. S., Camm, J., Ford, I., Lloyd, S. M., Komajda, M., Tavazzi, L., Talajic, M., Lainscak, M., Reil, J.-C., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.258 · Cited by 61
Self-citationRenal Denervation and Heart Failure
Böhm, M., Ewen, S., Kindermann, I., Linz, D., Ukena, C., & Mahfoud, F. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.83 · Cited by 61
Self-citationPacker, M., & Metra, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1857 · Cited by 61
Takada, T., Sakata, Y., Miyata, S., Takahashi, J. A., Nochioka, K., Miura, M., Tadaki, S., & Shimokawa, H. (2013) · European Journal of Heart Failure · doi:10.1002/ejhf.22 · Cited by 64
Böhm, M., Schumacher, H., Teo, K. K., Lonn, E. M., Mahfoud, F., Ukena, C., Mann, J. F. E., Mancia, G., Redon, J., Schmieder, R. E., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehy808 · Cited by 55
Self-citationBORER, J. S., Böhm, M., Ford, I., Robertson, M., Michel Komajda, N., Tavazzi, L., & Swedberg, K. B. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.10.033 · Cited by 52
Self-citationHeart Rate and its Reduction in Chronic Heart Failure and Beyond
Nikolovska Vukadinović, A., Vukadinović, D., Borer, J., Cowie, M., Komajda, M., Lainscak, M., Swedberg, K., & Böhm, M. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.902 · Cited by 52
Self-citationBöhm, M., Michel Komajda, N., BORER, J. S., Ford, I., Maack, C., Tavazzi, L., Moyne, A., & Swedberg, K. B. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1021 · Cited by 53
Self-citationSolal, A. C., Jacobson, A. F., & Piña, I. L. (2017) · ESC Heart Failure · doi:10.1002/ehf2.12153 · Cited by 54
“(iii) Recently, the SHIFT trial with ivabradine demonstrated heart rate as an important prognostic factor in HF patients with low LVEF and sinus rhythm.(9) This effect persisted after adjustment for baseline beta blocker dose.”
MethodGallet, R., Ternacle, J., Damy, T., Guendouz, S., Brémont, C., Seemann, A., Guéret, P., Dubois‐Randé, J., & Lim, P. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.07.093 · Cited by 50
“It decreases cardiovascular mortality and total mortality in chronic heart failure patients with elevated heart rate [13].”
BackgroundZugck, C., Martinka, P., & Stöckl, G. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0147-3 · Cited by 50
“(13 bpm) after 1 month resulted in a significant improvement in patient outcome at the end of follow-up [13].”
BackgroundMethodWang, C. C., Wu, C., Tsai, M., Lee, C., Huang, W. C., Chou, H., Huang, J. L., Chi, N., Yen, H., Tzeng, B., et al. (2019) · PubMed Central · doi:10.6515/acs.201905_35(3).20190422a · Cited by 54
Libhaber, E. N., Sliwa, K. S., Bachelier, K., Lamont, K. T., & Böhm, M. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.081 · Cited by 48
“Furthermore, in this cohort poor outcome was more prominent than in studies on stable heart failure populations on contemporary treatments as recommended by guidelines [19] even at an already elevated HR above 70 bpm [12] or even above 75 bpm [13].”
BackgroundResultInfluentialSelf-citationHirt, M. N., Muttardi, A., Helms, T. M., van den Bussche, H., & Eschenhagen, T. (2015) · Clinical Research in Cardiology · doi:10.1007/s00392-015-0939-8 · Cited by 47
“Further recommended options are ivabradine [7] for patients with a heart rate above 70 bpm despite an evidence-based dose of BBs [8] (more recent analyses [9] and the EMA approval suggest a heart rate above 75 bpm), cardiac glycosides [10] (with no proven mortality benefit) or cardiac resynchronization therapy (CRT-P/…”
Reduction of heart rate by omega-3 fatty acids and the potential underlying mechanisms
Kang, J. X. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00416 · Cited by 45
“Beta-adrenergic blockers, cardiotonic agents such as ivabradine, and ACE inhibitors have been prescribed for the purpose of lowering heart rate and reducing mortality, though they may present adverse effects (Arshad et al., 2008; Böhm et al., 2012).”
BackgroundAli, L., Wallström, S., Fors, A., Barenfeld, E., Fredholm, E. M., Fu, M. L. X., Goudarzi, M., Gyllensten, H., Kjellberg, I. L., Swedberg, K. B., et al. (2021) · Journal of Medical Internet Research · doi:10.2196/26794 · Cited by 48
Self-citationDEEDWANIA, P. C. (2013) · Drugs · doi:10.1007/s40265-013-0117-0 · Cited by 44
“[66] n = 2,052 n = 2,098 Primary composite endpoint 27 % 33 % 0.”
MethodOldenburg, O., Spießhöfer, J., Fox, H., Bitter, T., & Horstkotte, D. (2014) · Clinical Research in Cardiology · doi:10.1007/s00392-014-0784-1 · Cited by 47
Berliner, D., & Bauersachs, J. K. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0030 · Cited by 49
Böhm, M., Cammann, V. L., Ghadri, J. R., Ukena, C., Gili, S., Vece, D. D., Kato, K., Ding, K. J., Szawan, K. A., Micek, J., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1162 · Cited by 39
Self-citationCustodis, F., Roggenbuck, U., Lehmann, N., Moebus, S., Laufs, U., Mahabadi, A. A., Heusch, G., Mann, K., Jöckel, K., Erbel, R. M., et al. (2016) · Clinical Research in Cardiology · doi:10.1007/s00392-015-0956-7 · Cited by 42
Self-citationCowie, M., Schöpe, J., Wagenpfeil, S., Tavazzi, L., Böhm, M., Ponikowski, P. P., Anker, S. D., Filippatos, G. S., Michel Komajda, N., & QUALIFY Investigators (2021) · ESC Heart Failure · doi:10.1002/ehf2.13237 · Cited by 37
“A higher resting heart rate was associated with a higher probability of uptitration, which is clinically unsurprising as the drug’s initiation and uptitration should be modified by the resting heart rate.(16) By providing baseline and 18 month follow-up data on uptitration of recommended HFrEF disease-modifying medica…”
BackgroundSelf-citationThe therapeutic role of ivabradine in heart failure
Badu-Boateng, C., Jennings, R., & Hammersley, D. J. (2018) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622318784556 · Cited by 45
Ivabradine in Cardiovascular Disease Management Revisited: a Review
Chen, C., Kaur, G., Mehta, P. K., Morrone, D., Godoy, L. C., Bangalore, S., & Sidhu, M. S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07124-4 · Cited by 35
Anguita, M. P., Colet, J. C., Almenar, L., Crespo, M., Delgado, J. F., González-Costello, J., Hernández‐Madrid, A., Manito, N., de la Sota, E. P., Segovia, J. R., et al. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.07.013 · Cited by 33
Tebbe, U., Tschöpe, C., Wirtz, J. H., Lokies, J., Turgonyi, E., Bramlage, P., Strunz, A. M., Lins, K., & Böhm, M. (2014) · Clinical Research in Cardiology · doi:10.1007/s00392-014-0678-2 · Cited by 31
Self-citationKurgansky, K. E., Schubert, P. L., Parker, R., Djoussé, L., Riebman, J. B., GAGNON, D. R., & Joseph, J. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01384-6 · Cited by 31
Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes
Park, J. J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0239 · Cited by 38
Butler, J., Packer, M., Greene, S. J., Fiuzat, M., Anker, S. D., Anstrom, K. J., Carson, P. E., Cooper, L. B., Fonarow, G. C., Hernandez, A. F., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042155 · Cited by 30
Tsutsui, H., Momomura, S., Yamashina, A., Ogawa, H., Shimokawa, H., Kihara, Y., Saito, Y., Hagiwara, N., Ito, H., Ako, J., et al. (2016) · Circulation Journal · doi:10.1253/circj.cj-15-1112 · Cited by 29
van Buuren, F., Mellwig, K. P., Prinz, C., Körber, B., Fründ, A., Fritzsche, D., Faber, L., Kottmann, T., Bogunovic, N., Dahm, J. B., et al. (2013) · Clinical Research in Cardiology · doi:10.1007/s00392-013-0562-5 · Cited by 33
“It could be demonstrated that, beginning from a resting heart rate of [70 beats per minute, 5-bpm heart rate increments progressively increased the risk for cardiovascular death of CHF-induced hospital admission by 16 % [45].”
BackgroundResultAdvances in the management of heart failure: the role of ivabradine
Müller‐Werdan, U., Stöckl, G., & Werdan, K. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s90383 · Cited by 29
“This decision by the EMA is based on a retrospective analysis from the SHIFT study.(27) When analyzing the benefit of ivabradine medication in SHIFT in patients with an initial heart rate ≥ 75 b.”
Reil, J., Robertson, M., Ford, I., BORER, J. S., Komajda, M., Swedberg, K. B., Tavazzi, L., & Böhm, M. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft072 · Cited by 28
“m.(32) Furthermore, there was no significant association of LBBB with other adverse events such as blurred vision or phosphenes that are associated with ivabradine use.”
BackgroundResultSelf-citationBöhm, M., Robertson, M., BORER, J. S., Ford, I., Michel Komajda, N., Mahfoud, F., Ewen, S., Swedberg, K. B., & Tavazzi, L. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002160 · Cited by 29
Self-citationIvabradine for treatment of heart failure
Bocchi, E. A., & Salemi, V. M. C. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1612873 · Cited by 31
Heart rate: surrogate or target in the management of heart failure?
Böhm, M., & Reil, J. C. (2012) · Heart · doi:10.1136/heartjnl-2012-302301 · Cited by 28
Self-citationSanidas, E. A., Böhm, M., Oikonomopoulou, I., Dinopoulou, P., Papadopoulos, D. P., Michalopoulou, H., Tsioufis, K. P., Mancia, G., & Thomopoulos, C. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf291 · Cited by 29
Self-citationBöhm, M., Butler, J., Mahfoud, F., Filippatos, G. S., Ferreira, J. P., Pocock, S., Slawik, J., Brueckmann, M., Linetzky, B., Schueler, E., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2677 · Cited by 26
Self-citationBöhm, M., Lloyd, S. M., Ford, I., BORER, J. S., Ewen, S., Laufs, U., Mahfoud, F., Lopez-Sendon, J. L., Ponikowski, P. P., Tavazzi, L., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.493 · Cited by 25
Self-citationTherapeutic Use and Molecular Aspects of Ivabradine in Cardiac Remodeling: A Review
Kamisah, Y., & Hassan, H. H. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032801 · Cited by 29
“Nevertheless, three studies reported positive outcomes on mortality due to cardiovascular events or heart failure following ivabradine treatment [19,21,28] in patients with a resting heart rate higher than 75 beats per minute; however, these outcomes were not observed in patients with a lower resting heart rate [21].”
BackgroundMethodResultInfluentialBöhm, M., Ukena, C., Ewen, S., Linz, D., Živanović, I., Hoppe, U. C., Narkiewicz, K., Ruilope, L. M., Schlaich, M. P., Negoita, M., et al. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001085 · Cited by 25
“Apart from being a risk marker for these conditions, HR is a modifiable risk factor in heart failure [11], because its pharmacological reduction reduces the composite of heart failure hospitalization and cardiovascular death in heart failure patients with a HR more than 70 bpm [12] and cardiovascular death and total d…”
BackgroundSelf-citationSerum potassium and heart failure: association, causation, and clinical implications
Sfairopoulos, D., Arseniou, A., & Korantzopoulos, P. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10039-9 · Cited by 23
Quantification of radial arterial pulse characteristics change during exercise and recovery
Wang, A., Yang, L., Wen, W., Zhang, S., Hao, D., Khalid, S. G., & Zheng, D. (2016) · The Journal of Physiological Sciences · doi:10.1007/s12576-016-0515-7 · Cited by 23
Abumayyaleh, M., El‐Battrawy, I., Behnes, M., Borggrefe, M. M., & Akın, İ. (2020) · Future Cardiology · doi:10.2217/fca-2020-0002 · Cited by 24
Bouabdallaoui, N., O'Meara, E., Bernier, V., Komajda, M., Swedberg, K., Tavazzi, L., Borer, J. S., Bohm, M., Ford, I., & Tardif, J.-C. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12513 · Cited by 21
“Subgroup analyses demonstrated a constant improvement in outcomes across the whole spectrum of heart rate, with a significant relationship between baseline heart rate and treatment effect (higher being better).(2)”
BackgroundMethodSelf-citationHasenfuss, G. P., Anker, S. D., Bauersachs, J. K., Böhm, M., Hoppe, U. C., Pieske, B. M., von Scheidt, W., & Wachter, R. (2013) · Der Kardiologe · doi:10.1007/s12181-013-0491-6 · Cited by 28
Self-citationBORER, J. S., DEEDWANIA, P. C., Kim, J. B., & Böhm, M. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.08.089 · Cited by 21
Self-citationAll investigators of the HR-HF study, Fu, M. L. X., Ahrenmark, U., Berglund, S., Lindholm, C.-J., Lehto, A., Månsson‐Broberg, A., Tasevska-Dinevska, G., Wikström, G., Ågård, A., et al. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-017-1146-6 · Cited by 20
“The reason for this discrepancy is that survival benefit was shown in the SHIFT study in a subgroup with a heart rate of 75 bpm or higher [22].”
Hohneck, A. L., Fries, P., Stroeder, J., Schneider, G. K., Wagenpfeil, S., Schirmer, S. H., Böhm, M., Laufs, U., & Custodis, F. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000001984 · Cited by 22
“However, whereas HR reduction with the If channel inhibitor ivabradine (Iva) reduced outcomes in heart failure [10,11], a targeted HR reduction did not affect coronary events and outcome in patients with established stable CAD without heart failure [12,13].”
BackgroundSelf-citationIvabradine: potential clinical applications in critically ill patients
Santis, V. D., Vitale, D., Santoro, A., Magliocca, A., Porto, A. G., Nencini, C., & Tritapepe, L. (2012) · Clinical Research in Cardiology · doi:10.1007/s00392-012-0516-3 · Cited by 20
Ivabradine in the treatment of systolic heart failure - A systematic review and meta-analysis
Narayanan, M. A., Reddy, Y. N. V., Baskaran, J., Deshmukh, A. J., Benditt, D. G., & Raveendran, G. (2017) · World Journal of Cardiology · doi:10.4330/wjc.v9.i2.182 · Cited by 19
Optimization of Heart Failure Treatment by Heart Rate Reduction
Böhm, M., Bewarder, Y., Kindermann, I., Slawik, J., Wintrich, J., & Werner, C. M. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2019.0009 · Cited by 23
Self-citationDolliner, P., Hargitai, L., Graf, S., Huelsmann, M., Stiebellehner, L., Gleiß, A., Ubl, P., & Steurer, G. (2013) · Clinical Research in Cardiology · doi:10.1007/s00392-013-0563-4 · Cited by 18
“Based on the fact, that ACE-inhibitors and betablockers are strictly indicated in CHF [35–39], treatment native patients were not present in our cohort.”
BackgroundTime-updated resting heart rate predicts mortality in patients with COPD
Cohort, G. C., Omlor, A., Trudzinski, F. C., Alqudrah, M., Seiler, F., Biertz, F., Vogelmeier, C. F., Welte, T., Watz, H., Waschki, B., et al. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-019-01572-1 · Cited by 18
Self-citationGrassi, G. M., Seravalle, G., Vanoli, J., Facchetti, R., Spaziani, D., & Mancia, G. (2022) · Clinical Research in Cardiology · doi:10.1007/s00392-022-02028-9 · Cited by 16
“This means that this HR cutoff value applied in the SHIFT trial [4, 5], and the similar one used in other studies [6–10] is capable to detect HF patients with a lower or a higher neuroadrenergic cardiovascular drive.”
Anguita, M. P., Colet, J. C., Almenar, L., Crespo, M., Delgado, J. F., González‐Costello, J., Hernández‐Madrid, A., Manito, N., de la Sota, E. P., Segovia, J., et al. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2012.07.005 · Cited by 16
Role of the Funny Current Inhibitor Ivabradine in Cardiac Pharmacotherapy: A Systematic Review
Petite, S. E., Bishop, B. M., & Mauro, V. F. (2016) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000388 · Cited by 17
Laufs, U., Anker, S. D., Falk, V., Pieske, B. M., Baldus, S. E., Perings, C. A., & Birner, C. M. (2017) · Der Kardiologe · doi:10.1007/s12181-017-0143-3 · Cited by 15
“Auch wenn die europäische Zulassung von Ivabradin eine Herzfrequenz von mindestens 75/min fordert, unterstützen die Autoren die ESC-LL in diesem Punkt und empfehlen auf der Basis der Shift-Studie den Einsatz auch bei einer HF von 70/min [9].”
BackgroundIvabradine as adjuvant treatment for chronic heart failure
Benstoem, C., Kalvelage, C., Breuer, T., Heussen, N. M., Marx, G., Stoppe, C., & Brandenburg, V. M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013004.pub2 · Cited by 17
Corletto, A., Fröhlich, H., Täger, T., Hochadel, M., Zahn, R., Kilkowski, C., Winkler, R., Senges, J., Katus, H. A., & Frankenstein, L. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1277-4 · Cited by 20
What’s new in heart failure therapy 2018?†
Westphal, J. G., Bekfani, T., & Schulze, P. C. (2018) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivy282 · Cited by 20
Case Selection for Cardiac Resynchronization in Atrial Fibrillation
Cleland, J. G. F., Keshavarzi, F., Pellicori, P., & Dicken, B. (2013) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.07.001 · Cited by 15
Cavallari, I., Maddaloni, E., Nusca, A., Tuccinardi, D., Buzzetti, R., Pozzilli, P., & Grigioni, F. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00508-3 · Cited by 14
“Evidence CONSENSUS (enalapril) [55] CIBIS-II (bisoprolol) [19] RALES (spironolactone) [21] Intended use population in SHIFT [26] PARADIGM-HF [27] DAPA-HF (dapagliflozin) EMPERORReduced (empagliflozin) [28, 30, 31]”
BackgroundMethodInfluentialSummary and Comparison of the 2022 ACC/AHA/HFSA and 2021 ESC Heart Failure Guidelines
Badger, S., McVeigh, J., & Indraratna, P. (2023) · Cardiology and Therapy · doi:10.1007/s40119-023-00328-3 · Cited by 14
“Given the well-proven mortality benefits of beta-blocker therapy, these agents should be up-titrated to maximal tolerated doses prior to consideration of ivabradine initiation [29, 30].”
BackgroundNovel drugs for heart rate control in heart failure
Bielecka-Dabrowa, A. M., von Haehling, S., Rysz, J., & Banach, M. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9696-x · Cited by 14
Metadata
- Authors
- Böhm, M., Borer, J., Ford, I., Gonzalez-Juanatey, J. R., Komajda, M., Lopez-Sendon, J., Reil, J.-C., Swedberg, K., & Tavazzi, L.
- Affiliations
- Universitätsklinikum des Saarlandes (DE)
- SUNY Downstate Health Sciences University (US)
- University of Glasgow (GB)
- Hospital Universitario La Paz (ES)
- University of Gothenburg (SE)
- Maria Cecilia Hospital (IT)
- Corresponding author
- Böhm, Michael
- Reil, Jan-Christian
- ORCID
- Venue
- Clinical Research in Cardiology
- Published
- 2012-05-11
- Volume
- 102
- Issue
- 1
- Pages
- 11-22
- ISSN
- 1861-0684 (ISSN-L)
- 1861-0692
- OpenAlex
- W2045247934
- Cited by
- 248
- References
- 18
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 15 · 2023: 15 · 2022: 13 · 2021: 16 · 2020: 19 · 2019: 19 · 2018: 18 · 2017: 16 · 2016: 34 · 2015: 15 · 2014: 19 · 2013: 27 · 2012: 10
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Clinical Research in Cardiology (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Keywords
- ivabradine, chronic heart failure, baseline heart rate, SHIFT trial, cardiovascular mortality, heart failure hospitalization, heart rate reduction, all-cause mortality
- MeSH terms
- Ivabradine, Aged, Anti-Arrhythmia Agents, Benzazepines, Chronic Disease, Double-Blind Method, Female, Heart Failure, Heart Rate, Hospitalization, Humans, Male, Middle Aged, Risk Factors, Time Factors, Proportional Hazards Models, Treatment Outcome, Disease Progression, Risk Assessment, Patient Selection, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.